Gut–Brain Axis Modulation by Short-Chain Fatty Acids Exerts Disease-Modifying Effects in a Murine Model of Drug-Resistant Epilepsy - Report - MDSpire

Modulation of the Gut-Brain Axis by Short-Chain Fatty Acids Influences Disease Progression in a Mouse Model of Drug-Resistant Epilepsy

  • By

  • Akash A. Bera

  • Rossella Di Sapia

  • Greta Volpedo

  • Sneha Anand

  • Eray Sahin

  • Pasquale Baldassarre

  • Francesca Buffelli

  • Andrea Petretto

  • Chiara Lavarello

  • James D. Mills

  • Gabriele Cattaneo

  • Ilaria Craparotta

  • Eleonora Aronica

  • Antonella Riva

  • Pasquale Striano

  • Annamaria Vezzani

  • Teresa Ravizza

  • June 20, 2026

Share

Clinical Report: Modulation of the Gut-Brain Axis by Short-Chain Fatty Acids

Overview

This study investigates the effects of short-chain fatty acids (SCFAs) on seizure progression in a mouse model of drug-resistant epilepsy (DRE). Findings indicate that SCFA supplementation can attenuate seizures.

Background

Drug-resistant epilepsy (DRE) is a significant clinical challenge, affecting approximately one-third of individuals with epilepsy who do not achieve sustained seizure freedom with standard antiseizure medications. Current treatments primarily suppress seizures without addressing underlying mechanisms of epileptogenesis. The gut microbiota's role in DRE is increasingly recognized, with interventions like SCFA supplementation showing potential for disease modification.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • SCFA supplementation effectively attenuates seizure progression in a mouse model of DRE.
  • SCFA supplementation partially restored cerebral SCFA profiles in the treated mice.
  • Histopathological changes in both the brain and gut were normalized with SCFA supplementation.
  • Metabolomic profiling supports a multi-level modulatory effect of SCFAs on the gut-brain axis.

Clinical Implications

Further research is warranted to explore the clinical translation of these findings.

Conclusion

SCFAs warrant further investigation into their therapeutic applications in drug-resistant epilepsy.

Related Resources & Content

  1. Kwan P., Epilepsia, 2010 -- Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies
  2. Frontiers in Immunology, 2026 -- Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases
  3. Journal of Gastroenterology, 2023 -- Exploring the Role of Epigenetics in the Pathophysiology of Irritable Bowel Syndrome
  4. Brain, 2023 -- Exploring GABA Signaling Pathways within the Brain-Gut-Microbiome Interconnection
  5. Brain — Disruption of Chloride Homeostasis and GABA-Induced Depolarization in MTOR-Associated Cortical Development Anomalies
  6. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies - Kwan - 2010 - Epilepsia - Wiley Online Library
  7. Ketogenic diet therapies for the treatment of drug-resistant epilepsy in children and adults: A systematic review - PMC
  8. The alteration of gut microbiota composition in patients with epilepsy: A systematic review and meta-analysis - PubMed

Original Source(s)

Gut–Brain Axis Modulation by Short-Chain Fatty Acids Exerts Disease-Modifying Effects in a Murine Model of Drug-Resistant Epilepsy

  • by Akash A. Bera, Rossella Di Sapia, Greta Volpedo, Sneha Anand, Eray Sahin, Pasquale Baldassarre, Francesca Buffelli, Andrea Petretto, Chiara Lavarello, James D. Mills, Gabriele Cattaneo, Ilaria Craparotta, Eleonora Aronica, Antonella Riva, Pasquale Striano, Annamaria Vezzani, Teresa Ravizza

  • June 20, 2026

Related Content

Inhibition of tRNA fragments dysregulated in human mTLE exacerbates pathology and seizure activity

Remimazolam versus propofol on seizure adequacy in electroconvulsive therapy: a retrospective cohort study

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.